Evidence map›Paper›PMID 41836059›Full record

ArticleFrontiers in genetics2026

Allelic diversity of the pharmacogenes CYP2D6 and CYP2C19 in Māori from Te Tairāwhiti, Aotearoa New Zealand.

Leonie Hitchman, Te Whetu Aarahi Kerekere, Allison L Miller, Elizabeth Goodin, Caroline Koia, Huti Watson, Frances King, Stephen P Robertson, Phillip Wilcox, Martin A Kennedy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leonie HitchmanDepartment of Pathology and Molecular Medicine, University of Otago, Christchurch, New Zealand.
Te Whetu Aarahi KerekereDepartment of Pathology and Molecular Medicine, University of Otago, Christchurch, New Zealand.
Allison L MillerDepartment of Pathology and Molecular Medicine, University of Otago, Christchurch, New Zealand.
Elizabeth GoodinDepartment of Womens and Childrens Health, University of Otago, Dunedin, New Zealand.
Caroline KoiaNgāti Porou Oranga, Gisborne, New Zealand.
Huti WatsonNgāti Porou Oranga, Gisborne, New Zealand.
Frances KingNgāti Porou Oranga, Gisborne, New Zealand.
Stephen P RobertsonDepartment of Womens and Childrens Health, University of Otago, Dunedin, New Zealand.
Phillip WilcoxDepartment of Mathematics and Statistics, University of Otago, Dunedin, New Zealand.
Martin A KennedyDepartment of Pathology and Molecular Medicine, University of Otago, Christchurch, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CYP2C19 and CYP2D6 are two important pharmacogenes responsible for metabolising a wide range of medications. Both genes exhibit a high level of variation, which can lead to variable activity of the enzymes they encode, with risks of adverse drug reactions and treatment failure. Understanding this variation is therefore of great importance, but the full extent of variability in these genes is not yet documented, particularly for understudied populations. We employed targeted nanopore sequencing to identify genetic variants within

Indexed as

CYP2C19CYP2D6diversitydrug metabolism (human and animal)drug responseindigeneousnanopore sequencing

Identifiers

PMID41836059
PMCPMC12981722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.